Edgewise Therapeutics, Inc. Depreciation
Edgewise Therapeutics, Inc. (EWTX) reported Depreciation of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Edgewise Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $500.00K, a 0.00% change year-over-year.
- Edgewise Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $537.00K, a 4.68% increase year-over-year.
- Edgewise Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $525.00K, a 9.01% decline year-over-year.
- Edgewise Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $500.00K, a 0.00% change year-over-year.
- Edgewise Therapeutics, Inc. depreciation for fiscal 2025 was $2.08M, a 0.72% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. depreciation for fiscal 2024 was $2.07M, a 33.40% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. depreciation for fiscal 2023 was $1.55M, a 321.47% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. depreciation for fiscal 2022 was $368.00K, a 35.29% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-06 | $1.08M 10-Q · filed 2026-08-06 | $1.56M derived: sum of 3 quarters · filed 2026-08-06 | $2.06M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $537.00K 10-Q · filed 2026-05-07 | $1.06M derived: sum of 2 quarters · filed 2026-05-07 | $1.56M derived: sum of 3 quarters · filed 2026-05-07 | $2.06M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $525.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.02M derived: sum of 2 quarters · filed 2026-02-26 | $1.52M derived: sum of 3 quarters · filed 2026-08-06 | $2.08M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-06 | $1.00M derived: sum of 2 quarters · filed 2026-08-06 | $1.56M 10-Q · filed 2025-11-06 | $2.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-06 | $1.04M 10-Q · filed 2026-08-06 | $1.59M derived: sum of 3 quarters · filed 2026-08-06 | $2.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $513.00K 10-Q · filed 2026-05-07 | $1.09M derived: sum of 2 quarters · filed 2026-05-07 | $1.59M derived: sum of 3 quarters · filed 2026-05-07 | $2.09M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $577.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.08M derived: sum of 2 quarters · filed 2026-02-26 | $1.58M derived: sum of 3 quarters · filed 2026-02-26 | $2.07M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-06 | $1.00M derived: sum of 2 quarters · filed 2025-11-06 | $1.49M 10-Q · filed 2025-11-06 | $1.96M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $500.00K 10-Q · filed 2025-08-07 | $953.00K 10-Q · filed 2025-08-07 | $1.46M derived: sum of 3 quarters · filed 2026-02-26 | $1.86M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $473.00K 10-Q · filed 2025-05-08 | $956.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.36M derived: sum of 3 quarters · filed 2026-02-26 | $1.76M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $883.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.28M derived: sum of 3 quarters · filed 2026-02-26 | $1.55M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $400.00K 10-Q · filed 2024-11-07 | $800.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.07M 10-Q · filed 2024-11-07 | $1.08M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-08 | $619.00K 10-Q · filed 2024-08-08 | $683.00K derived: sum of 3 quarters · filed 2024-08-08 | $783.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $195.00K 10-Q · filed 2024-05-09 | $283.00K derived: sum of 2 quarters · filed 2024-05-09 | $383.00K derived: sum of 3 quarters · filed 2024-05-09 | $483.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $188.00K derived: sum of 2 quarters · filed 2024-02-22 | $288.00K derived: sum of 3 quarters · filed 2024-02-22 | $368.00K 10-K · filed 2024-02-22 | |
| 2022-09-30 | $100.00K 10-Q · filed 2023-11-09 | $200.00K derived: sum of 2 quarters · filed 2023-11-09 | $280.00K 10-Q · filed 2023-11-09 | $361.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $100.00K 10-Q · filed 2023-08-10 | $97.00K 10-Q · filed 2022-08-04 | $180.00K 10-Q · filed 2023-08-10 | $261.00K derived: sum of 3 quarters · filed 2023-08-10 | $361.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $83.00K 10-Q · filed 2023-05-11 | $161.00K derived: sum of 2 quarters · filed 2023-05-11 | $261.00K derived: sum of 3 quarters · filed 2023-05-11 | $312.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $178.00K derived: sum of 2 quarters · filed 2023-02-23 | $229.00K derived: sum of 3 quarters · filed 2023-02-23 | $272.00K 10-K · filed 2023-02-23 | |
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-03 | $64.00K 10-Q · filed 2021-11-10 | $151.00K derived: sum of 2 quarters · filed 2022-11-03 | $194.00K 10-Q · filed 2022-11-03 | $280.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $51.00K 10-Q · filed 2022-08-04 | $130.00K 10-Q · filed 2022-08-04 | $180.00K derived: sum of 3 quarters · filed 2022-08-04 | $229.00K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $79.00K 10-Q · filed 2022-05-11 | $129.00K derived: sum of 2 quarters · filed 2022-05-11 | $178.00K derived: sum of 3 quarters · filed 2022-05-11 | $224.00K derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $99.00K derived: sum of 2 quarters · filed 2022-02-24 | $145.00K derived: sum of 3 quarters · filed 2022-02-24 | $185.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $49.00K 10-Q · filed 2021-11-10 | $95.00K derived: sum of 2 quarters · filed 2021-11-10 | $135.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $46.00K 10-Q · filed 2021-08-09 | $85.00K 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $40.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |